CurrentCommunity-CarePolicy N/A

Tocilizumab (medical benefit) utilization

This policy governs medical benefit coverage criteria, quantity limits, and authorization periods for tocilizumab and its biosimilars for rheumatologic indications and specifies provider, diagnostic, and prior-therapy requirements for members in the payer's jurisdiction.

Policy Summary

PayerCommunity-Care

PolicyTocilizumab (medical benefit) utilization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateFeb 1, 2025

Key ActionSubmit prior authorization with specialty, diagnosis, dates and doses of conventional DMARD therapy (including methotrexate dosing and duration) or documented intolerance/contraindication and patient weight for dosing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

MultipleIndications listed

400 mg/28dQty limit (RA/paJIA/AOSD)

600 mg/28dQty limit (GCA)

LifetimeAuth period (RA/paJIA/AOSD)

1 yearAuth period (GCA)

Coverage Criteria for Tocilizumab

Initial Therapy — Rheumatoid Arthritis

Covered when ALL of the following are met

RA initial criteria: Prescribed by a rheumatology specialist; diagnosis of rheumatoid arthritis; trial of one or more conventional DMARDs (e.g., methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, corticosteroids) alone or in combination that included methotrexate ≥ 20 mg/week for at least 8 weeks within a 3-month period; either no response after 3 months (no change in SDAI or CDAI) or did not reach goal at 6 months (goal defined as remission or low disease activity by SDAI/CDAI thresholds); provide dates and doses of conventional DMARD therapy and dates of methotrexate ≥ 20 mg/week; list dose-limiting side effects or contraindications to methotrexate if applicable (a contraindication does not cancel the requirement of a 3–6 month trial of conventional DMARDs).methotrexate >= 20 mg/week for ≥8 weeks; SDAI/CDAI response thresholds

No response defined as no change in SDAI or CDAI; 6-month goal defined as SDAI 0.0–3.3 (remission) or 3.4–11.0 (low disease activity) and CDAI 0.0–2.8 (remission) or 2.9–10.0 (low disease activity).

Initial Therapy — Polyarticular Juvenile Idiopathic Arthritis

Covered when ANY of the following alternate paths are met (documented in request)

Policy Summary

PayerCommunity-Care

PolicyTocilizumab (medical benefit) utilization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateFeb 1, 2025

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

paJIA initial criteria: Prescribed by a rheumatology specialist; diagnosis of polyarticular juvenile idiopathic arthritis; intolerance or documented contraindication to methotrexate (reason provided), OR failed monotherapy with methotrexate ≥ 15 mg/m2/week for >3 months.methotrexate >= 15 mg/m2/week for >3 months

Reason for intolerance or contraindication must be provided in the request.

Initial Therapy — Giant Cell Arteritis

Covered when ALL of the following are met

GCA initial criteria: Prescribed by, or in consultation with, a rheumatologist; diagnosis of giant cell arteritis (GCA) positively confirmed by one of the following: temporal artery biopsy, Doppler ultrasound, magnetic resonance angiography (MRA), or positron emission tomography (PET).objective diagnostic confirmation by listed tests

Objective diagnostic test required for initial coverage.

Initial Therapy — Systemic Juvenile Idiopathic Arthritis

Covered when ALL of the following are met

systemic JIA initial criteria: Prescribed by a rheumatologist; diagnosis of systemic juvenile idiopathic arthritis.diagnosis documented

Specialist prescriber required.

Initial Therapy — Adult-onset Still's Disease

Covered when ALL of the following are met

AOSD initial criteria: Prescribed by a rheumatologist; diagnosis of moderate-to-severe, active adult-onset Still's disease.disease severity documented

Specialist prescriber required.

Continuation Therapy — Giant Cell Arteritis

Covered when ALL of the following are met

GCA continuation criteria: Diagnosis of giant cell arteritis (GCA); documentation that the patient requires continued use of tocilizumab to prevent relapse of GCA.clinical need to prevent relapse

If approved, continuation coverage for GCA is allowed for 1 year (subject to benefit changes).

None explicitly listed in this policy. The document does not specify any exclusions or conditions that categorically prohibit coverage for tocilizumab; coverage is governed by the indication-specific criteria and documentation requirements described elsewhere in the policy.

Requests lacking required documentation may be denied. Specifically, the policy requires submission of dates and doses of conventional DMARD therapy and dates of methotrexate ≥ 20 mg/week (or the methotrexate dosing appropriate to pediatric JIA). Failure to provide these details, or failure to provide objective diagnostic confirmation when required for an indication, may render the request not approved.

Coding and Dosing Details

Applicable HCPCS CodesHCPCSCovered

J3262	Injection, tocilizumab, 1 mg
Q5133	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Q5135	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg

Methotrexate trial — dosing thresholds for RA and polyarticular JIA

Rheumatoid arthritis methotrexate trialMethotrexate ≥ 20 mg/week for at least 8 weeks within a 3-month trial period

Requirement when no response at 3 monthsMember must have used methotrexate ≥ 20 mg/week for 8 weeks during that 3-month period

Documentation requiredProvide dates of utilization and doses of methotrexate ≥ 20 mg/week

Note on contraindicationA contraindication to methotrexate does not cancel the requirement of a 3–6 month trial of conventional DMARDs

Examples of other conventional DMARDs and target dosesOptimal therapeutic dosing: sulfasalazine ≥ 2 g/day; hydroxychloroquine 400 mg/day; leflunomide 20 mg/day

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required. Submit specialty, diagnosis, and prior conventional DMARD therapy details (including methotrexate dosing and duration) with the initial request.

Specialty: rheumatology (or rheumatology consult for GCA)
Diagnosis: specific diagnosis (e.g., rheumatoid arthritis, giant cell arteritis)
Prior DMARD therapy: dates, agents, doses, and duration (see conventional DMARD trial requirement below)

Step Therapy

Conventional DMARD Trial Required

For rheumatoid arthritis, a trial of one or more conventional disease-modifying antirheumatic drugs (DMARDs) is required prior to approval. The trial must include documentation of methotrexate at a therapeutic dose and duration unless contraindicated or intolerant.

Examples of conventional DMARDs: methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, corticosteroids
Methotrexate requirement: ≥ 20 mg/week for at least 8 weeks (member must have used methotrexate ≥ 20 mg/week for 8 weeks during a 3-month period and no response after 3 months or failure to reach treatment goal at 6 months)
Optimal dosing examples: sulfasalazine ≥ 2 g/day; hydroxychloroquine 400 mg/day; leflunomide 20 mg/day
If methotrexate is contraindicated or not tolerated, document the reason; note that a contraindication does not automatically waive the requirement for a 3–6 month trial of other conventional DMARDs

Documentation Required

Required Clinical Documentation

Provide complete clinical documentation with the authorization request. Incomplete documentation may result in denial or delay.

Diagnosis and relevant clinical history
Prescriber specialty: rheumatology (or rheumatology consult for GCA)
Dates, doses, and duration of all prior conventional DMARD therapies
Specific dates of methotrexate use and dose (document methotrexate ≥ 20 mg/week where applicable)
If applicable, list dose-limiting side effects or contraindications to methotrexate with supporting clinical detail
For giant cell arteritis (GCA): objective confirmation required by temporal artery biopsy, Doppler ultrasound, MRA, or PET
For GCA continuation requests: documentation that the patient requires continued tocilizumab to prevent relapse

Denial Risk

Documentation and Denial Risk

Failure to provide the required dates and doses of conventional DMARD therapy, including documentation of methotrexate dosing when applicable, or failure to provide objective confirmation of GCA, may result in denial of the request.

Missing methotrexate dates/doses (including lack of documentation of ≥ 20 mg/week use) may trigger denial
Lack of objective diagnostic confirmation for GCA (temporal artery biopsy, Doppler ultrasound, MRA, or PET) may trigger denial
Missing prescriber specialty or rheumatology consult documentation may delay approval

Background

Tocilizumab is indicated in this policy for several inflammatory rheumatologic conditions, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, and adult-onset Still's disease. The policy requires specialist prescribing (rheumatology) and, depending on the indication, objective diagnostic confirmation or documented trials of conventional disease-modifying antirheumatic drugs (DMARDs) including specified methotrexate dosing and duration before approval.

Definitions and Clinical Targets

No response — Defined as no change in the Simple Disease Activity Index (SDAI) or Clinical Disease Activity Index (CDAI) score.

DefinitionNo response is defined as no change in the Simple Disease Activity Index (SDAI) or Clinical Disease Activity Index (CDAI) score.

Context of useApplied when evaluating response after a 3-month conventional DMARD trial (including methotrexate ≥ 20 mg/week)

Implication for approvalLack of change in SDAI/CDAI supports continued consideration for biologic therapy per policy criteria

6-month goal — Remission or low disease activity defined as SDAI 0.0-3.3 or 3.4-11.0 and CDAI 0.0-2.8 or 2.9-10.0 respectively.

Remission (SDAI)SDAI score 0.0–3.3

Low disease activity (SDAI)SDAI score 3.4–11.0

Remission (CDAI)CDAI score 0.0–2.8

Low disease activity (CDAI)CDAI score 2.9–10.0

6-month goal applicationGoal at 6 months is remission or low disease activity by the SDAI/CDAI thresholds above

Revision History

February 2025last_reviewLatest

Policy last reviewed in February 2025 (document-level review date).